2型糖尿病的合理药物治疗:2002至2020年丹麦关于死亡率、糖尿病相关结局、不良事件与药物费用的数据
该研究随访2002至2020年丹麦2型糖尿病 population,分析药物使用与治疗获益、不良事件及药物费用的关系。共纳入461,805人,期间心血管、肾脏等重要不良临床结局发生率下降,部分不良事件减少但电解质紊乱和酮症酸中毒增加。人均药物费用降低8%,总药物费用因人群扩大而增加148%。
要点
- 2002至2020年丹麦2型糖尿病患者心血管、肾脏等重要不良临床结局发生率下降。
- 胃出血、低血糖和跌倒发生率下降,而电解质紊乱和酮症酸中毒发生率增加。
- 人均药物费用降低8%,但总药物费用因人群扩大增加148%。
核心结论
- 2型糖尿病管理的进步降低了糖尿病相关结局和治疗伤害的风险,同时人均药物费用保持相对稳定;这些趋势提示更合理的药物治疗,但某些不良事件风险增加和降糖药物费用上升仍需持续警惕和风险获益分析。
研究设计与样本
- 研究随访2002至2020年丹麦2型糖尿病 population,分析药物使用与治疗获益、不良事件及药物费用的关系,并使用多变量分析调整年龄、性别和社会经济地位等潜在混杂因素。
- 研究共纳入461,805人。
主要发现
- 2002至2020年,中位年龄从66岁增至68岁,平均合并症数量从5.2增至8.8。
- 心血管、肾脏及其他重要不良临床结局的总体发生率下降。
- 胃出血、低血糖和跌倒等不良事件发生率下降,而电解质紊乱和酮症酸中毒发生率增加。
- 人均药物费用降低8%,但总药物费用因人群规模扩大、大多数心血管药物费用降低及降糖药物费用增加而增加148%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Developments in pharmacotherapy and management of type 2 diabetes may have shifted the balance of treatment benefits versus harms and costs over the past decades. This study aimed to describe the trends in this balance. RESEARCH DESIGN AND METHODS: We followed the Danish population with type 2 diabetes between 2002 and 2020, analyzing their medication use in relation to treatment benefits (such as mortality and diabetes-related outcomes), adverse events, and medication costs. Using multivariate analyses, we adjusted for potential confounders, including age, sex, and socioeconomic status. RESULTS: The study included 461,805 individuals. From 2002 to 2020, the median age increased from 66 to 68 years, and the mean number of comorbidities increased from 5.2 to 8.8. The overall incidence of cardiovascular, renal, and other important adverse clinical outcomes decreased. Similarly, the rate of some adverse events, such as gastric bleeding, hypoglycemia, and falls declined, whereas the incidence of electrolyte imbalances and ketoacidosis increased. The average per-patient cost was reduced by 8%, but total medication expenses increased by 148% due to an expanding population size, lowered costs of most cardiovascular medications, and increasing costs for glucose-lowering drugs. CONCLUSIONS: Advancements in type 2 diabetes management have led to reduced risk of both diabetes-related outcomes and treatment harms, while maintaining relatively stable per-patient medication expenses. Although these trends are multifactorial, they suggest more rational pharmacotherapy. Still, increased risk of certain adverse events, along with increasing costs for glucose-lowering medications, underscores the need for ongoing vigilance and risk-benefit analysis.
引用
- Johansson KS, Jimenez-Solem E, Petersen TS, et al. Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses. Diabetes Care. 2024. PMID: 38995637. doi:10.2337/dc24-0619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。